Transaction #30639 · Form 4 · 0001193125-26-414500
Tango Therapeutics, Inc. · Exercise / conversion · Common Stock
Tango Therapeutics, Inc. · Transacted October 1, 2026 · Filed October 5, 2026
What does this filing report?
An SEC Form 4 filing for Tango Therapeutics, Inc. records an exercise / conversion involving Common Stock on October 1, 2026. The reported quantity was 27,000. The filing date is October 5, 2026. This is one transaction record; amounts are not allocated among any joint reporting owners.
The acquisition category describes how securities were received. It does not by itself establish a cash purchase of common stock. Read the transaction code definitionsand the original filing before interpreting the amounts.
Transaction details
- Company
- Tango Therapeutics, Inc.
- Company CIK
- 0001819133
- Security type
- Non-derivative
- Acquisition type
- Exercise / conversion · Code M
- Quantity acquired
- 27,000
- Reported price
- 5.2
- Reference value
- 140,400
- Currency
- Currency not specified
- Ownership
- Direct
- Holdings after transaction
- 142,743
- Ownership description
- Not reported
- SEC acceptance time
- Oct 5, 2026, 5:36 PM EDT
- 10b5-1 indication
- Indicated in filing
Reference value is reported quantity × reported price. It is not a confirmed cash payment or an estimate of a derivative's economic value. A missing currency is not assumed to be USD.
Reporting owners
- Crystal Adam ↗
President, R&D
CIK 0001825445
These are the reporting owners named in the filing. Quantities and amounts are not allocated among co-reporters. Roles reflect this filing, not a current profile.
Company listings
The linked listing is identified separately from other current company listings.
Filing footnotes & remarks
- F1
- These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on October 27, 2025.
- F2
- Represents the weighted average sales price per share. The shares sold at prices ranging from $23.96 to $24.95 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
- F3
- Represents the weighted average sales price per share. The shares sold at prices ranging from $25.04 to $25.41 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
- F4
- This option shall vest and become exercisable over a four-year period, at a rate of 25% on February 27, 2024, with the remaining option shares vesting in 36 equal monthly installments thereafter.
Footnotes are reproduced as plain text from the current source filing. For the full context, read the original SEC filing.
This record was updated Eastern Time. This is the stored record update time, not the transaction date. Report a correction.